These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18157138)

  • 1. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.
    Bauer TR; Allen JM; Hai M; Tuschong LM; Khan IF; Olson EM; Adler RL; Burkholder TH; Gu YC; Russell DW; Hickstein DD
    Nat Med; 2008 Jan; 14(1):93-7. PubMed ID: 18157138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.
    Bauer TR; Tuschong LM; Calvo KR; Shive HR; Burkholder TH; Karlsson EK; West RR; Russell DW; Hickstein DD
    Mol Ther; 2013 May; 21(5):964-72. PubMed ID: 23531552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.
    Bauer TR; Olson EM; Huo Y; Tuschong LM; Allen JM; Li Y; Burkholder TH; Russell DW
    Gene Ther; 2011 Jun; 18(6):553-9. PubMed ID: 21228879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.
    Hunter MJ; Tuschong LM; Fowler CJ; Bauer TR; Burkholder TH; Hickstein DD
    Mol Ther; 2011 Jan; 19(1):113-21. PubMed ID: 20859258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.
    Bauer TR; Hai M; Tuschong LM; Burkholder TH; Gu YC; Sokolic RA; Ferguson C; Dunbar CE; Hickstein DD
    Blood; 2006 Nov; 108(10):3313-20. PubMed ID: 16868255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.
    Hunter MJ; Zhao H; Tuschong LM; Bauer TR; Burkholder TH; Persons DA; Hickstein DD
    Hum Gene Ther; 2011 Jun; 22(6):689-96. PubMed ID: 21275758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1.
    Smith RH; Bloomer H; Fink D; Keyvanfar K; Nasimuzzaman M; Sancheznieto F; Dutta R; Guenther Bui K; Alvarado LJ; Bauer TR; Hickstein DD; Russell DW; Malik P; van der Loo JCM; Highfill SL; Kuhns DB; Pirooznia M; Larochelle A
    Hum Gene Ther; 2022 Dec; 33(23-24):1293-1304. PubMed ID: 36094106
    [No Abstract]   [Full Text] [Related]  

  • 8. Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency.
    Nelson EJ; Tuschong LM; Hunter MJ; Bauer TR; Burkholder TH; Hickstein DD
    Gene Ther; 2010 May; 17(5):672-7. PubMed ID: 20164857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy.
    Hai M; Adler RL; Bauer TR; Tuschong LM; Gu YC; Wu X; Hickstein DD
    Gene Ther; 2008 Jul; 15(14):1067-71. PubMed ID: 18369320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Foamy virus vectors come of age.
    Williams DA
    Mol Ther; 2008 Apr; 16(4):635-6. PubMed ID: 18362918
    [No Abstract]   [Full Text] [Related]  

  • 11. Conversion of the severe to the moderate disease phenotype with donor leukocyte microchimerism in canine leukocyte adhesion deficiency.
    Gu YC; Bauer TR; Sokolic RA; Hai M; Tuschong LM; Burkholder T; Bacher J; Starost MF; Hickstein DD
    Bone Marrow Transplant; 2006 Mar; 37(6):607-14. PubMed ID: 16444276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
    Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking of specific integrant clones in dogs treated with foamy virus vectors.
    Ohmine K; Li Y; Bauer TR; Hickstein DD; Russell DW
    Hum Gene Ther; 2011 Feb; 22(2):217-24. PubMed ID: 20738155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus.
    Beard BC; Keyser KA; Trobridge GD; Peterson LJ; Miller DG; Jacobs M; Kaul R; Kiem HP
    Hum Gene Ther; 2007 May; 18(5):423-34. PubMed ID: 17518616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.
    Sokolic RA; Bauer TR; Gu YC; Hai M; Tuschong LM; Burkholder T; Colenda L; Bacher J; Starost MF; Hickstein DD
    Biol Blood Marrow Transplant; 2005 Oct; 11(10):755-63. PubMed ID: 16182176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foamy virus vectors: an awaited alternative to gammaretro- and lentiviral vectors.
    Rethwilm A
    Curr Gene Ther; 2007 Aug; 7(4):261-71. PubMed ID: 17969559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative hematopoietic stem cell transplantation corrects the disease phenotype in the canine model of leukocyte adhesion deficiency.
    Bauer TR; Gu YC; Tuschong LM; Burkholder T; Bacher JD; Starost MF; Donahue RE; Sokolic RA; Hickstein DD
    Exp Hematol; 2005 Jun; 33(6):706-12. PubMed ID: 15911095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.
    Trobridge GD; Beard BC; Wu RA; Ironside C; Malik P; Kiem HP
    PLoS One; 2012; 7(9):e45173. PubMed ID: 23028826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large animal models for foamy virus vector gene therapy.
    Trobridge GD; Horn PA; Beard BC; Kiem HP
    Viruses; 2012 Dec; 4(12):3572-88. PubMed ID: 23223198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canine leukocyte adhesion deficiency colony for investigation of novel hematopoietic therapies.
    Creevy KE; Bauer TR; Tuschong LM; Embree LJ; Colenda L; Cogan K; Starost MF; Haskins ME; Hickstein DD
    Vet Immunol Immunopathol; 2003 Jul; 94(1-2):11-22. PubMed ID: 12842608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.